Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
SAN DIEGO, May 16, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that it will present at the 18th Annual B. Riley & Co. Institutional Investor Conference at 09:00 AM Pacific Time (12 PM Eastern Time) on Wednesday, May 24, 2017. The presentation will take place in the Arcadia D room at the Lowes Santa Monica Beach Hotel, in Santa Monica, CA. Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments.
Cytori management will be available for one-on-one meetings at the conference. Attending investors who are interested in meeting management are encouraged to contact their B. Riley representative or Cytori ([email protected]).
A live audio and video webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com (http://ir.cytori.com). A replay of the presentation will be available for 30 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Cytori Therapeutics
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.
About B. Riley & Co., LLC
B. Riley & Co., LLC is a leading investment bank providing advisory, research, and sales & trading to corporate, institutional and high net worth individual clients. Investment banking services include M&A advisory and debt and equity offerings. The firm is nationally recognized for its highly ranked proprietary equity research. B. Riley & Co. is a member of FINRA and SIPC. For more information, please visit www.brileyco.com.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 [email protected]
